- Drugmakers eye the biosimilars market
Generic-drug makers are increasingly focused on producing biosimilars because of the segment's competitive advantage and ability to bring high profit margins, according to a report from Frost & Sullivan. "The trend is shifting towards less competitive, yet commercially attractive segments such as difficult-to-produce generics, specialty generics and biosimilars," as governments worldwide try to curb health care costs, firm analyst Aiswariya Chidambaram said. PharmaTimes (U.K.) (1/17)        - BrainStorm's stem cell treatment for ALS appears safe in study
BrainStorm Cell Therapeutics said initial results of a clinical trial show that adult stem cell therapy NurOwn is safe for patients with amyotrophic lateral sclerosis. The study involves transplanting cells derived from patients' bone marrow. Researchers are preparing to expand the trial to determine the treatment's efficacy. Reuters (1/17) - Pfizer and Medivation stop work on Dimebon
Medivation and Pfizer will end development of Dimebon for all therapeutic indications after the drug did not achieve primary endpoints in a study that combined it with Aricept, a standard treatment for mild to moderate Alzheimer's disease. The drug was previously tested by itself as a treatment for Alzheimer's. The Wall Street Journal (1/18) - Researchers make headway in stem cell trials
Studies to be presented at a conference in San Diego will highlight the progress of stem cell treatments in clinical trials. One of the studies encompasses the use of mesenchymal stem cells in treating the adverse effects of radiation. Another study covers the use of an allogenic supportive cell therapy to restore motor function after stroke. Genetic Engineering & Biotechnology News (1/15)  | Principles of Checkweighing - Building an Effective Program
This essential guide is an invaluable resource of checkweighing information and a definitive reference providing an insight into all aspects of checkweighing from basic principles to implementation of a comprehensive program. Request your free copy now! |
 | Company & Financial News |  |  | | - Janssen opens life science center in California
Janssen Research & Development has created a life science center called Janssen Labs in San Diego. The 30,000-square-foot center will provide startup biotech companies with flexible lab environment, allowing them to rent space and lab equipment on a short-term basis. Diomics, Neurolixis, Tem Systems and Yolia Health will be the first residents of the center. Genetic Engineering & Biotechnology News (1/17) | Drug Development Basic Training | | | | - Biosimilar development in a virtual biotech environment (Part I)
Finox Biotech was founded late in 2007 as a virtual company and has made considerable progress in developing its first biosimilar, Afolia, a recombinant-human follicle-stimulating hormone. In this article, the first part of two, the co-founder and CEO of Finox Biotech describes in detail the company's target selection and approach to choosing the right partners. Check back next week for Part II. |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Valero to pour $50M in Mascoma's cellulosic-ethanol project
Valero Energy is planning to invest $50 million in Mascoma's proposed cellulosic-ethanol plant in Michigan. Mascoma received $23.5 million in state funding and is awaiting approval of a $210 million federal loan guarantee for the project, which is estimated to cost $350 million. Construction is slated to begin this year with production to start in 2013. Energy Business Review (1/17) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | Never tell people how to do things. Tell them what to do and they will surprise you with their ingenuity."
--George S. Patton,
U.S. Army general  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, January 17, 2012
- Monday, January 16, 2012
- Friday, January 13, 2012
- Thursday, January 12, 2012
- Wednesday, January 11, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment